• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Introduction

Escitalopram is a selective serotonin reuptake inhibitor (SSRI) widely prescribed for major depressive disorder (MDD) and generalized anxiety disorder (GAD). It is the S‑enantiomer of citalopram, developed to enhance efficacy and tolerability while reducing dose‑dependent side effects. First approved in the early 2000s, escitalopram has become one of the most commonly used antidepressants due to its favorable balance of effectiveness, safety, and minimal drug‑drug interactions.

Pharmacology

Escitalopram acts by binding to the serotonin transporter (SERT) with high affinity, blocking the reuptake of serotonin into the presynaptic neuron. This increases serotonin levels in the synaptic cleft, enhancing serotonergic neurotransmission. Unlike racemic citalopram, which contains both R- and S-enantiomers, escitalopram is the isolated active form. The R‑enantiomer of citalopram does not contribute to antidepressant activity but may antagonize the effect of escitalopram and increase the risk of QT prolongation. Escitalopram has negligible affinity for other neurotransmitter receptors (e.g., adrenergic, dopaminergic, histaminergic), resulting in fewer side effects compared to older antidepressants.

The drug is well absorbed orally with a bioavailability of ~80%. Peak plasma concentrations occur after 3–5 hours. It is metabolized primarily by CYP2C19, CYP2D6, and ; https://Farmaciazotti.it/images/products/amoxil.webp, CYP3A4 enzymes. The elimination half‑life is about 27–32 hours, allowing once‑daily dosing. Escitalopram reaches steady state within one week.

Clinical Indications

Escitalopram is approved for:

• Major depressive disorder (MDD)
  
• Generalized anxiety disorder (GAD)
  
• Social anxiety disorder
  
• Panic disorder with or without agoraphobia
  
• Obsessive‑compulsive disorder (OCD)
  

It is also used off‑label for premenstrual dysphoric disorder, post‑traumatic stress disorder, and eating disorders.

Efficacy

Numerous randomized controlled trials and meta‑analyses confirm escitalopram’s efficacy in MDD and GAD. In MDD, it is at least as effective as other SSRIs (e.g., paroxetine, sertraline) and venlafaxine, with a faster onset of action reported in some studies. Response rates typically reach 50–60% after 8 weeks. For GAD, escitalopram reduces psychic and somatic symptoms significantly compared to placebo. A Cochrane review noted that escitalopram is among the best‑tolerated SSRIs, with fewer discontinuations due to adverse events. Comparative effectiveness studies suggest escitalopram may have a slight advantage in achieving remission in moderate‑to‑severe depression.

Dosage and Administration

Therapeutic doses for MDD and GAD range from 10 to 20 mg once daily. Treatment is usually initiated at 10 mg; some patients may start at 5 mg for the first week to minimize activation side effects. Higher doses (20 mg) are reserved for patients who do not respond adequately to 10 mg. The full therapeutic response may take 2–4 weeks, with maximal benefit by 8–12 weeks. In elderly patients or those with hepatic impairment, a lower dose (5–10 mg) is recommended.

Adverse Effects

Escitalopram is generally well tolerated. Common side effects (<10%) include nausea, diarrhea, dry mouth, somnolence, insomnia, increased sweating, and sexual dysfunction (delayed ejaculation, anorgasmia). These are mostly transient. Nausea can be minimized by taking the drug with food. Weight gain is modest (2–3 kg on average). Serotonin syndrome is rare but serious when escitalopram is combined with other serotonergic agents (e.g., MAOIs, linezolid, triptans).

A notable concern is the dose‑dependent QT interval prolongation observed with citalopram. However, escitalopram has a much lower risk: at therapeutic doses (10–20 mg), QTc prolongation is minimal and generally not clinically significant. Nevertheless, caution is warranted in patients with pre‑existing heart disease, electrolyte imbalances, or those taking other QT‑prolonging drugs.

Withdrawal syndrome (discontinuation syndrome) can occur if escitalopram is stopped abruptly, characterized by dizziness, paresthesia, headache, nausea, and anxiety. Gradual dose tapering over several weeks is recommended.

Drug Interactions

Escitalopram has a low potential for pharmacokinetic interactions because it does not significantly inhibit or induce major CYP enzymes. However, it is a substrate of CYP2C19, CYP2D6, and CYP3A4. Inhibitors of these isoenzymes (e.g., omeprazole for CYP2C19, fluoxetine for CYP2D6) can increase escitalopram levels. Conversely, inducers (e.g., carbamazepine, St. John’s wort) may reduce its efficacy. Serotonergic drugs, including MAOIs, triptans, tramadol, and lithium, increase the risk of serotonin syndrome.

Escitalopram does not potentiate the effects of alcohol, but patients are advised to limit alcohol use due to additive CNS depression.

Special Populations

• Pregnancy and lactation: Use should be considered only if the potential benefit outweighs risk. SSRIs have been associated with persistent pulmonary hypertension in newborns and neonatal adaptation syndrome. Escitalopram is excreted into breast milk in low amounts.
  
• Children and adolescents: Escitalopram is approved for MDD in adolescents (12–17 years). A black box warning for increased suicidal ideation applies, as with all antidepressants.
  
• Elderly: Lower starting doses are advisable, and close monitoring for hyponatremia (SIADH) and falls is recommended.
  
  

Conclusion

Escitalopram remains a first‑line pharmacotherapy for MDD and GAD due to its robust efficacy, good tolerability, and favorable safety profile relative to other antidepressants. Its once‑daily dosing, low interaction potential, and reduced QT risk compared to citalopram make it a convenient choice. Clinicians should be aware of the potential for sexual side effects, discontinuation syndrome, and the rare possibility of serotonin syndrome when combining with other serotonergic agents. With appropriate patient selection and monitoring, escitalopram offers a valuable tool in the management of mood and anxiety disorders.